Time: 10:00 AM - 10:20 AM
Location: Samhällsvetarhuset, Hörsal B
The event is for: students - anyone - employees
In pioneering articles 2011/2012, Emmanuelle Charpentier published the discovery of the programmable mechanism of the so-called CRISPR-Cas9 system, which is part of the bacteria’s own immune system against virus attacks. CRISPR-Cas9 is currently used in laboratories all over the world for targeted editing of genes in all kinds of living organisms for biotechnology, biomedical and gene-therapeutic purposes and has been one of the most important discoveries for life science research in recent years. Emmanuelle Charpentier, together with colleagues, has also founded CRISPR Therapeutics and ERC Genomics, companies that promote the development of therapies against severe genetic diseases.
Emmanuelle Charpentier will be awarded the title Honorary doctor of medicine at the Annual Celebration Ceremony on 21 October at 17:00 in Aula Nordica.